Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration

Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration

Abstract While there has been significant progress in the development of rapid COVID-19 diagnostics, as the pandemic unfolds, new challenges have emerged, including whether these technologies can reliably detect the more infectious variants of concern and be viably deployed in non-clinical settings...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jennifer K. Frediani, Joshua M. Levy, Anuradha Rao, Leda Bassit, Janet Figueroa, Miriam B. Vos, Anna Wood, Robert Jerris, Van Leung-Pineda, Mark D. Gonzalez, Beverly B. Rogers, Maud Mavigner, Raymond F. Schinazi, Nils Schoof, Jesse J. Waggoner, Russell R. Kempker, Paulina A. Rebolledo, Jared W. O’Neal, Cheryl Stone, Ann Chahroudi, Claudia R. Morris, Allie Suessmith, Julie Sullivan, Sarah Farmer, Amanda Foster, John D. Roback, Thanuja Ramachandra, CaDeidre Washington, Kristie Le, Maria C. Cordero, Annette Esper, Eric J. Nehl, Yun F. Wang, Erika A. Tyburski, Greg S. Martin, Wilbur A. Lam
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/30016094be9f470888a58161d2407fd5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract While there has been significant progress in the development of rapid COVID-19 diagnostics, as the pandemic unfolds, new challenges have emerged, including whether these technologies can reliably detect the more infectious variants of concern and be viably deployed in non-clinical settings as “self-tests”. Multidisciplinary evaluation of the Abbott BinaxNOW COVID-19 Ag Card (BinaxNOW, a widely used rapid antigen test, included limit of detection, variant detection, test performance across different age-groups, and usability with self/caregiver-administration. While BinaxNOW detected the highly infectious variants, B.1.1.7 (Alpha) first identified in the UK, B.1.351 (Beta) first identified in South Africa, P.1 (Gamma) first identified in Brazil, B.1.617.2 (Delta) first identified in India and B.1.2, a non-VOC, test sensitivity decreased with decreasing viral loads. Moreover, BinaxNOW sensitivity trended lower when devices were performed by patients/caregivers themselves compared to trained clinical staff, despite universally high usability assessments following self/caregiver-administration among different age groups. Overall, these data indicate that while BinaxNOW accurately detects the new viral variants, as rapid COVID-19 tests enter the home, their already lower sensitivities compared to RT-PCR may decrease even more due to user error.

Ejemplares similares